Equities analysts forecast that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will report sales of $72.96 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Ironwood Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $72.80 million and the highest estimate coming in at $73.12 million. Ironwood Pharmaceuticals posted sales of $87.46 million in the same quarter last year, which suggests a negative year-over-year growth rate of 16.6%. The firm is expected to issue its next earnings results on Tuesday, February 20th.
On average, analysts expect that Ironwood Pharmaceuticals will report full year sales of $72.96 million for the current year, with estimates ranging from $256.82 million to $269.10 million. For the next fiscal year, analysts anticipate that the business will report sales of $364.23 million per share, with estimates ranging from $348.22 million to $391.50 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.07. The firm had revenue of $86.80 million for the quarter, compared to analyst estimates of $73.59 million. Ironwood Pharmaceuticals had a negative return on equity of 399.91% and a negative net margin of 48.89%. The business’s quarterly revenue was up 31.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.18) EPS.
Several equities research analysts recently weighed in on IRWD shares. Zacks Investment Research raised shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 17th. J P Morgan Chase & Co reaffirmed a “neutral” rating and set a $19.00 target price (down from $20.00) on shares of Ironwood Pharmaceuticals in a research note on Friday, July 21st. Wood & Company downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Friday, July 21st. Mizuho reaffirmed a “buy” rating and set a $22.00 target price on shares of Ironwood Pharmaceuticals in a research note on Sunday, July 23rd. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $20.00 target price on shares of Ironwood Pharmaceuticals in a research note on Sunday, July 23rd. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $18.29.
Ironwood Pharmaceuticals (NASDAQ:IRWD) traded up $0.70 during trading hours on Wednesday, hitting $15.87. The company’s stock had a trading volume of 1,670,000 shares, compared to its average volume of 1,410,000. Ironwood Pharmaceuticals has a 52-week low of $12.76 and a 52-week high of $19.94. The company has a current ratio of 4.27, a quick ratio of 4.27 and a debt-to-equity ratio of 79.64.
Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Ironwood Pharmaceuticals by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 10,761,867 shares of the biotechnology company’s stock valued at $203,184,000 after purchasing an additional 256,406 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter valued at approximately $150,460,000. State Street Corp boosted its holdings in shares of Ironwood Pharmaceuticals by 13.7% in the 2nd quarter. State Street Corp now owns 4,530,267 shares of the biotechnology company’s stock valued at $85,533,000 after buying an additional 545,464 shares in the last quarter. EcoR1 Capital LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 29.2% in the 2nd quarter. EcoR1 Capital LLC now owns 3,753,635 shares of the biotechnology company’s stock valued at $70,869,000 after buying an additional 848,120 shares in the last quarter. Finally, Pictet Asset Management Ltd. boosted its holdings in shares of Ironwood Pharmaceuticals by 37.5% in the 3rd quarter. Pictet Asset Management Ltd. now owns 2,622,507 shares of the biotechnology company’s stock valued at $41,357,000 after buying an additional 715,147 shares in the last quarter. 97.88% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “$72.96 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/11/04/72-96-million-in-sales-expected-for-ironwood-pharmaceuticals-inc-irwd-this-quarter.html.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Ironwood Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ironwood Pharmaceuticals Inc. and related companies.